Hawthorn executes deal with university
MADISON — Hawthorn Pharmaceuticals Inc. has struck a global licensing deal with the University of Pittsburgh covering a series of novel monoclonal antibodies for cancer.
Under the terms of the agreement, Madison-based Hawthorn will receive an exclusive worldwide license to develop and commercialize the antibody portfolio.
“We are excited to be working with the world=-class cancer scientists at University of Pittsburgh’s Cancer Institute who have devoted their entire careers to improving people’s lives through cancer discovery,” said Rob Lewis, chief scientific officer at Hawthorn.
“There are many strengths created by our relationship with the University of Pittsburgh that promotes the rapid development of these novel antibodies,” said Max Draughn, president and CEO of Hawthorn. “Our collaboration is a shared vision to ultimately extend and improve the lives of many children and adults who suffer with various cancers.”
To sign up for Mississippi Business Daily Updates, click here.
Top Posts & Pages
- Alumni-couple donate $12.3M to Mississippi State
- IKE TROTTER: There are primary changes in Social Security for 2014
- MAN OF STEEL: Madhu Ranade leading Severstal Columbus
- Town given Obamacare insurance break, but faces additional costs in 2015
- TRIP releases report on state's crumbling roads, bridges
- Butler Snow Advisory Services adds Jimmy Bailey
- Expert on airlines predicts Jackson-Evers will keep remaining carriers
- MDA to lead delegation on mission to Europe
- C Spire launches next phase of 1-gig service rollout
- Public meeting called to mull future of convention center